Adults Craniopharyngiomas: Modern Management and Changes in the Paradigm
Emmanuel Jouanneau, MD, PhD
Hospices Civils of Lyon - Lyon University
Session Description
Recent advances in molecular biology support a reframing of current treatment strategies for papillary craniopharyngiomas. recent studies confirms that combined BRAF-MEK inhibition can induce a rapid and sustained objective response in these tumors, with encouraging benefits on the associated clinical syndrome and good overall tolerability. Neoadjuvant medical treatment may represent a safe and efficient option for invasive papillary craniopharyngiomas, to facilitate a safer definitive treatment on smaller target volumes, thus improving treatment-related morbidity.